A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ.
Witzig TE, et al. Among authors: maurer mj.
Am J Hematol. 2013 Jul;88(7):589-93. doi: 10.1002/ajh.23460. Epub 2013 Jun 12.
Am J Hematol. 2013.
PMID: 23619698
Free PMC article.
Clinical Trial.